UroGen Pharma price target lowered to $55 from $64 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $55 from $64 and keeps a Buy rating on the shares. The company reported a “modest” revenue miss, but its long-term outlook is “still promising,” the analyst tells investors in a research note.